Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) insider Dan Karlin sold 6,871 shares of the company’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $5.98, for a total transaction of $41,088.58. Following the sale, the insider now directly owns 344,656 shares of the company’s stock, valued at approximately $2,061,042.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Mind Medicine (MindMed) Trading Down 0.7 %
Shares of NASDAQ MNMD opened at $5.85 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 5.92 and a current ratio of 5.92. Mind Medicine has a 52-week low of $2.41 and a 52-week high of $12.22. The firm has a 50 day moving average price of $6.81 and a two-hundred day moving average price of $7.99. The stock has a market cap of $420.45 million, a P/E ratio of -1.99 and a beta of 2.53.
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.18). As a group, equities analysts forecast that Mind Medicine will post -1.27 EPS for the current year.
Hedge Funds Weigh In On Mind Medicine (MindMed)
Analysts Set New Price Targets
A number of analysts have recently weighed in on MNMD shares. Roth Mkm started coverage on shares of Mind Medicine (MindMed) in a report on Wednesday, July 24th. They set a “buy” rating and a $36.00 price target for the company. Roth Capital raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a report on Wednesday, July 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mind Medicine (MindMed) in a research note on Friday, June 21st. Canaccord Genuity Group dropped their price objective on shares of Mind Medicine (MindMed) from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $22.00 price objective on shares of Mind Medicine (MindMed) in a research note on Wednesday, June 5th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.38.
Check Out Our Latest Report on Mind Medicine (MindMed)
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Featured Stories
- Five stocks we like better than Mind Medicine (MindMed)
- What is Put Option Volume?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Market Cap Calculator: How to Calculate Market Cap
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Stock Market Upgrades: What Are They?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.